Tumor-Induced Osteomalacia (Oncogenic Osteomalacia)⁶⁸Ga-DOTATATE · ⁶⁸Ga-FAPI · ¹¹¹In-octreotide

Quick Answer

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which a usually tiny, benign phosphaturic mesenchymal tumor (PMT) secretes FGF23, causing renal phosphate wasting, hypophosphatemia, low/inappropriately-normal 1,25-vitamin D, and disabling osteomalacia (bone pain, fractures, weakness). The clinical problem is not diagnosing the biochemistry but finding the occult tumor — often millimetric, in bone or soft tissue anywhere from skull to feet. Because PMTs express somatostatin receptors, ⁶⁸Ga-DOTATATE PET/CT is the functional localizer of choice (superior to older ¹¹¹In-octreotide), with FDG and increasingly ⁶⁸Ga-FAPI as complements; a suspected focus is then confirmed anatomically (CT/MRI) and, ideally, by selective venous sampling for FGF23 before curative resection.

The biochemical setup

A PMT oversecretes FGF23, a phosphaturic hormone that down-regulates renal phosphate reabsorption (and suppresses 1,25-dihydroxyvitamin D). The result is chronic hypophosphatemia with renal phosphate wasting and defective bone mineralization (osteomalacia). Recognizing the pattern — unexplained hypophosphatemia with high/inappropriate FGF23, bone pain and fragility fractures — is what triggers the imaging tumor hunt.

Finding the tumor

These tumors are small and can hide anywhere, so whole-body functional imaging is essential:

After localization

Complete surgical resection of the PMT is curative — FGF23 falls within hours and phosphate normalizes over days, with osteomalacia healing thereafter. When the tumor cannot be found or resected, medical therapy (phosphate + active vitamin D, or FGF23-pathway–directed therapy) controls the biochemistry. The nuclear-medicine contribution is decisive: DOTATATE PET frequently locates a tumor that years of conventional imaging missed.

High-Yield Pearls

• TIO = FGF23-secreting phosphaturic mesenchymal tumor → renal phosphate wasting, hypophosphatemia, osteomalacia.
• The challenge is localization; ⁶⁸Ga-DOTATATE PET/CT (SSTR) is the first-line functional search, better than ¹¹¹In-octreotide.
• FAPI and FDG are complements when DOTATATE is negative.
• Resection is curative — FGF23 and phosphate normalize rapidly.

Common Pitfalls

• Managing the hypophosphatemia indefinitely without an aggressive DOTATATE-PET tumor hunt.
• Assuming a negative ¹¹¹In-octreotide scan excludes a tumor — DOTATATE PET is more sensitive.
• Over-calling incidental physiologic/degenerative SSTR or FAPI uptake as the culprit without anatomic/biochemical confirmation.

Related Pages

• Tracers: ⁶⁸Ga-DOTATATE, FAPI; therapy context: PRRT / theranostics.

Differential Diagnosis

• Other FGF23-mediated hypophosphatemia without a tumor — X-linked (XLH) and autosomal-dominant (ADHR) hypophosphatemic rickets are germline, present in childhood with a family history, and have no culprit lesion to localize.
• Non-FGF23 renal phosphate wasting — Fanconi syndrome, drugs (tenofovir, ifosfamide), and IV iron-induced FGF23 elevation cause phosphaturia without a PMT.
• Nutritional/vitamin-D-deficiency osteomalacia — different biochemistry (phosphate wasting is secondary, driven by hyperparathyroidism), no FGF23 excess.
• SSTR-PET false positives mimicking the culprit — physiologic uncinate-process/splenunculus/adrenal uptake, degenerative joint uptake, and other SSTR-expressing lesions (meningioma, neuroendocrine tumor, granuloma).
• FAPI false positives — arthritis, healing insufficiency fractures, and inflammation are FAPI-avid, a real trap in TIO patients who characteristically have fragility fractures.

Reporting Checklist

• Confirm whole-body coverage from skull to feet (extend fields to hands and feet) — PMTs commonly lodge at acral/extremity sites outside the routine PET range.
• Report each SSTR-avid focus with size, uptake versus background, bone-vs-soft-tissue location, and a precise anatomic description for surgical mapping.
• Provide the CT/MRI correlate and state whether disease appears solitary or multifocal.
• Distinguish a likely culprit from physiologic, degenerative, or inflammatory uptake.
• If imaging is equivocal or multifocal, recommend selective venous sampling for FGF23; if negative, recommend a complementary tracer (FAPI or FDG).

Self-Check

Key References

• Reviews of ⁶⁸Ga-DOTATATE (and FAPI) PET/CT for localizing occult phosphaturic mesenchymal tumors in TIO.
• Endocrine literature on FGF23 physiology, TIO diagnosis, and surgical cure.